Role of consolidation therapy in Multiple Myeloma. Pieter Sonneveld. Erasmus MC Cancer Institute Rotterdam The Netherlands
|
|
- Juliet Higgins
- 5 years ago
- Views:
Transcription
1 Role of consolidation therapy in Multiple Myeloma Pieter Sonneveld Erasmus MC Cancer Institute Rotterdam The Netherlands
2 Disclosures Research support : Amgen, Celgene, Janssen, Karyopharm Advisory Boards/Honoraria: BMS, Amgen, Celgene, Janssen, Karyopharm
3 What is consolidation therapy in TE NDMM? Additional therapy following 1 st ASCT with the goal of maintaining or even improving a stable response, before end of treatment or entering any maintenance therapy. 2 nd ASCT Additional cycles like in remission induction VTD, VRD, Bortezomib, TD Other chemotherapy (alternate, salvage)
4 Consolidation + Maintenance vs Maintenance alone PFS OS Cons/Main Main Al Ani et al, Eur J Haemat 2017
5 2nd ASCT
6 Single versus double ASCT in MM IFM94 trial VGPR after first ASCT Absence of VGPR after first ASCT P<0.001 P=0.7 Attal et al. N Engl J Med 2003;349:
7 Bologna 96 trial: single vs double ASCT All pts < ncr RFS RFS EFS EFS OS OS M. Cavo et al. JCO2007
8 HOVON65/GMMG HD4 : PFS and OS by treatment arm HOVON (single) & GMMG (double) OS@96m Treatment VAD single HDT 10% 44% PAD single HDT 18% 42% VAD double HDT 10% 47% PAD double HDT 16% 55% PAD + double ASCT the best option Sonneveld P, et alash 2015 Abstr 27.
9 Multivariate Cox analysis of HOVON65/GMMG HD4 on OS Bortezomib arm only Patients in HOVON centres received single ASCT Patients in GMMG centres received tandem transplant
10 EMN02/HO95 MM trial: study design VCD induction x 3-4 cycles + PBSC collection R1 VMP x 4 cycles Bortezomib 1.3 mg/m 2 d 1,4,8,11,22,25,29,32/42 Melphalan 9 mg/m 2 d 1-4/42 Prednisone 60 mg/m 2 d 1-4/42 (497 pts) Melphalan (HDM) 200 mg/m 2 x 1 or 2 courses* + single or double ASCT (695 pts) R2 VRD consolidat ion x 2 cycles No consolidat ion Maintenan ce lenalidomi de Stratification factor: ISS I vs. II vs. III Randomization to VMP or HDM was 1:1 in centres with a fixed single ASCT policy * Randomization to VMP or HDM-1 or HDM-2 was 1:1:1 in centers with a double ASCT policy Cavo M, et al. Presented at ASH 2017 (Abstract 397)
11 PFS by randomization (ASCT-1 vs ASCT-2) % (66.2% ; 79.4%) ASCT-1 ASCT-2 PFS probability % (57.3% ; 71.5%) HR: 0.71 (95% CI, ), P=0.040 HR: 0.71 (95% CI, ), P=0.040 ASCT-1 ASCT Months Number at risk Months
12 PFS by randomization and cytogenetic risk ASCT-1 vs ASCT-2 by High Risk ASCT-2 by Standard or High Risk ASCT-1 ASCT-2 High risk ( 1/3 CA) Standard risk (0/3 CA) PFS probability Median PFS: ASCT-2: NR; ASCT-1: 26.7 mos HR: 0.42 (95% CI, ), P= % (54.7% ; 87.5%) 44.2% (31% ; 63.2%) PFS probability HR: 0.79 (95% CI, ), P=0.483 HR: 0.79 (95% CI, ), P= % (54.7% ; 87.5%) 76.4% (69.2% ; 84.5%) ASCT-1 ASCT Months Number at risk Months Months Number at risk Months
13 Changes in response categories* after ASCT-2 SD PR VGPR CR scr 71% 24% % 38% % 36% 5% % 13% % 10% 0 ASCT-1 ASCT-2 *As reported by study investigators. Central reassessment of response categories is ongoing
14 Consolidation with chemotherapy
15 Phase 3: VTD vs TD (GIMEMA study) Impact of consolidation (triplet vs doublet) Per protocol analysis: n=321, received entire treatment program VTD TD p CR post-consolidation 61% 47% CR/nCR post-consolidation 73% 61% Upgrade to CR post-consolidation 30.4% 16.6% Landmark analysis from start of consolidation (30 months median follow up) 3-yr probability of relapse or progression 38% 52% yr PFS 62% 46% Superior PFS with VTD vs TD consolidation retained across poor prognosis subgroups: t(4;14) and/or del(17q), del(13q) β 2 M >3.5 mg/l, LDH >190 U/L, ISS stage 2 and 3 Cavo et al. Lancet 2012
16 VTD consolidation (IFM) Retrospective analysis of IFM: assessment of VTd consolidation after VTd induction and single ASCT (VTd-auto-VTd) Cohort 1 (n=121) VTd ASCT VTd consolidation Cohort 2 (n=76) VTd ASCT no consolidation (IFM ) Cohort 3 (n=40) VCd, VRd ASCT, no consolidation ORR at completion of therapy 86% 94% 80% CR at completion of therapy 53% 34% 32.5% Rate of relapse 21% 55% 32.5% Death 8% 8% 20% 0.07 Median PFS Not reached 32 mos 30 mos Free of relapse at 32 months 54.5% 32% 32% Median OS Not reached Not reached 38 mos ns 3 year OS 84% 91% 76% ns P Leleu et al. ASH 2012 (Abstract 3096)
17 VRD for induction and consolidation Roussel M et al, JCO 2014
18 Car/Len/Dex Consolidation after ASCT Phase 2 trial in NDMM, transplant eligible 42 evaluable patients 4cyclesof K36Rd induction, 2 cycles consolidation ORR 94%, CR 69%, VGPR 23% CR 25% (RI), 45% (ASCT), 69% (Cons) MRD NGS 59% Roussel M et al, ASH 2016
19 KTd: Treatment Schedule in NDMM Induction 4 cycles Carfilzomib 20/27mg/m 2 days 1,2,8,9,15,16 of a 28 day cycle. Thalidomide 200 mg daily Dexamethasone 40 mg once a week Intensification 1 cycle HDM 200 mg/m 2 ASCT Consolidation 4 cycles Carfilzomib 27mg/m 2 days 1,2,8,9,15,16 of a 28 day cycle. Thalidomide 50 mg daily Dexamethasone 40 mg once a week 4 dose levels: 20/27mg/m 2 20/36mg/m 2 20/45mg/m 2 20/56mg/m 2 Cohort 5: 8 induction cycles Sonneveld et al. Blood 2015
20 Response Wester et al. ASH 2017
21 Progression-free survival and overall survival Wester et al. ASH 2017
22 What is the role of Consolidation in Three trials: the current era? IFM2009 study (Attal et al, NEJM, 2017, 376, 14) CTN0702 (Stadtmauer et al, ASH 2016) EMN02/HO95 (Sonneveld et al, ASH 2016)
23 IFM/DFCI 2009 Parallel Phase 3 Study Newly Diagnosed MM (SCT candidates; # 1360;
24 Lenalidomide, bortezomib and dexamethasone with transplantation : IFM2009 HR 0.65, 95% CI 0.53, 0.8; p< Attal et al, NEJM, 2017, 376, 14
25 Lenalidomide, bortezomib and dexamethasone with transplantation : IFM2009 Attal et al, NEJM, 2017, 376, 14 Attal et al, NEJM, 2017, 376, 14
26 Attal et al, NEJM, 2017, 376, 14 Attal et al, NEJM, 2017, 376, 14
27 Attal et al, NEJM, 2017, 376, 14 (supplementary) Avet Loiseau et al, ASH 2017
28 BMT CTN 0702 Stem Cell Transplantation for Multiple Myeloma Incorporating Novel Agents: SCHEMA N=750 pts (250 in each arm) Lenalidomide Maintenance ** Register and Randomize N=257 MEL 200mg/m 2 VRD x 4* N=254 Lenalidomide Maintenance** *Bortezomib 1.3mg/m 2 days 1, 4, 8,11 Lenalidomide 15mg days 1 15 Dexamethasone 40mg days 1, 8, 15 Every 21 days MEL 200mg/m 2 N=247 Lenalidomide Maintenance** 1 st presentation at ASH 2016 Slides courtesy of Prof Ed Stadtmauer **Lenalidomide x 3years : 10mg/d for 3 cycles, then 15 mg/d Amendment in 2014 changed Lenalidomide maintenance until disease progression after report of CALGB
29 BMT CTN 0702: Demographics Treatment Arm ASCT/ASCT (N=247) ASCT/RVD (N=254) ASCT/Maint (N=257) Disease Risk N % N % N % High risk Standard risk Gender Male Female Karnofsky Performance Score 90% Cytogenetic Abnormalities t(4;14) t(14;16) t(14;20) del(17p) del(13q) by CA
30 BMT CTN 0702: Regimens prior to Transplant Auto/Auto (N=247) Auto/RVD (N=254) Auto/Maint (N=257) N % N % N % Initial Therapy Bort/Len/Dex Cy/Bort/Dex Len/Dex Bort/Dex Other Bort, bortezomib; Cy, cyclophosphamide; Dex, dexamethasone; Len, lenalidomide Stadtmauer 30et al, ASH 2016
31 Probability, % Primary Endpoint: Progression free Survival 0 38 Month Estimate and 95% CI Auto/Auto: 56.5 (49.4, 62.9) Auto/RVD: 56.7 (50.0, 62.8) Auto/Maint: 52.2 (45.4, 58.6) Months from Randomization N at risk Auto/Auto Auto/RVD Auto/Maint Slides courtesy of Prof Ed Stadtmauer Stadtmauer et al, ASH 2016
32 100 Overall Survival Probability, % Month Estimate and 95% CI Auto/Auto: 82.0 (76.3, 86.5) Auto/RVD: 85.7 (80.5, 89.5) Auto/Maint: 83.4 (77.9, 87.7) Months from Randomization N at risk Auto/Auto Auto/RVD Auto/Maint Slides courtesy of Prof Ed Stadtmauer Stadtmauer et al, ASH 2016
33 PFS & OS Standard Risk Multiple Myeloma PFS OS Slides courtesy of Prof Ed Stadtmauer Stadtmauer et al, ASH 2016
34 PFS & OS High Risk Multiple Myeloma PFS OS Slides courtesy of Prof Ed Stadtmauer Stadtmauer et al, ASH 2016
35 EMN02/HO95 MM trial: study design VCD induction x 3-4 cycles + PBSC collection R1 VMP x 4 cycles Bortezomib 1.3 mg/m 2 d 1,4,8,11,22,25,29,32/42 Melphalan 9 mg/m 2 d 1-4/42 Prednisone 60 mg/m 2 d 1-4/42 (497 pts) Melphalan (HDM) 200 mg/m 2 x 1 or 2 courses* + single or double ASCT (695 pts) R2 VRD consolidat ion x 2 cycles No consolidat ion Maintenan ce lenalidomi de Stratification factor: ISS I vs. II vs. III Randomization to VMP or HDM was 1:1 in centers with a fixed single ASCT policy * Randomization to VMP or HDM-1 or HDM-2 was 1:1:1 in centers with a double ASCT policy
36 Response status at time of 2 nd randomization no consolidation VRD Patients, # Last treatment, % HDM 1 HDM 2 VMP Best response before R2, % scr CR VGPR PR < PR / unknown
37 Upgrade of response with consolidation no consolidation VRD Patients, # Best response before R2, % scr CR VGPR PR Best response after R2, % scr CR VGPR PR * * Statistically significant 37
38 100 Progression-free free survival Cumulative percentage VRD no consolidation 0 no consolidation VRD N 435 F 137 no consolidation VRD Cox LR P=0.045 (adjusted for 1st random.) months 36 At risk: HR = 0.78 ( ) EMN / HO95 MM
39 Planned subgroup analysis for PFS PFS from consolidation randomization Characteristic Events/Patients VRD no consol HR & 95% CI (VRD : no consol) Reduction (SD) ISS stage 1 37 / / / / / / 76 Cytogenetic risk: high = del(17p) and/or standard 55 / / 248 high 34 / / 83 unknown 30 / / 110 Intensification randomization VMP 43 / / 155 HDM 72 / / 280 not randomized 4 / 8 2 / 6 Total 119 / / 441 (26%) (32%) %(16) increase 2P=0.07 no consol VRD better better EMN02 / HO95 MM 39
40 Outcome (PFS) in FISH and MRD risk groups FISH High vs Standard risk FISH + MRD Oliva et al, ASH 2017
41 IFM2009, CTN 702 & EMN02 compilation IFM2009 n=700 CTN702 n=702 EMN02 n=1192 Med. Age (range) 60 (29,66) 58 (52, 63) FISH HR Definition t(4;14), t(14;16), 17 del t(4;14), t(14;16), t(14;20), 17 del t(4;14), t(14;16), 17 del FISH HR (%) ISS III (%) 18 9 Induction VRD 81.5% Bort based VCD Consolidation VRD VRD/2 nd ASCT VRD Tandem ASCT No Yes, per protocol Yes, per clinician (received in 68% assigned) Maintenance Lena for 1 yr Lena for 3 yrs un l PD Lena until PD Med PFS (mns) (No ASCT/ASCT) 36 vs 50 PFS@ (%) HR mns (M/Con/ASCT): 52 vs 56.7 vs 56.5 OS@ (%) (No ASCT/ASCT) 82 vs 81 (No ASCT/ASCT) NR vs mns (M/RVD/ASCT2): 83 vs 85 vs 82 3yrs (No ASCT/ASCT) 57 vs 65 3yrs (No ASCT/ASCT) 84.6 vs 86.3 SPM (%) 7.4 vs vs 6 vs 5.6 No difference
42 Daratumumab-VTd trial in transplant eligible NDMM IFM /Hovon131/MMY3006 registration trial Cassiopeia n=1080 R Endpoints: scr PFS, OS Induction 4 cycles VTD + Dara VTD* q 4 w HDM ASCT Consolidation 2 cycles VTD + Dara VTD* q 4 w Ongoing, recruitment completed Stratify by: dara treatment, response, MRD status R Maintenance for 2 years Dara Observation
43 Conclusions Consolidation therapy improves response, quality and PFS, possibly OS In general 2 or 3 consolidation cycles are safe and effective Efficacy of 2 nd ASCT confirmed in EMN02
44 Controversies & Questions Impact on OS What is the optimal CONS regimen and # of cycles Should CONS use the same regimen as induction Which subgroups benefit from CONS Is CONS by chemo or by 2 nd ASCT equal What is efficacy of CONS if followed by maintenance Is CONS equally effective in treatments with novel agents Should we dose CONS based on MRD status Cost issues Lack of prospective data
45
46
47 x
Initial Therapy For Transplant-Eligible Patients With Multiple Myeloma. Michele Cavo, MD University of Bologna Bologna, Italy
Initial Therapy For Transplant-Eligible Patients With Multiple Myeloma Michele Cavo, MD University of Bologna Bologna, Italy Treatment Paradigm for Autotransplant-Eligible Patients With Multiple Myeloma
More informationInduction Therapy in Transplant Eligible MM 2 December Tontanai Numbenjapon, M.D.
Induction Therapy in Transplant Eligible MM 2 December 2017 Tontanai Numbenjapon, M.D. What we need from induction therapy in NDMM Depth of response: MRD-negative, scr, CR Longest response Acceptable toxicity
More informationConsolidation and Maintenance therapy
University of Salamanca Consolidation and Maintenance therapy María-Victoria Mateos, MD, PhD University Hospital of Salamanca, Spain Disclosure form MVM has served as member of advisory boards or received
More informationIs autologous stem cell transplant the best consolidation after initial therapy?
Is autologous stem cell transplant the best consolidation after initial therapy? William Bensinger, MD Professor of Medicine, Division of Oncology University of Washington School of Medicine Director,
More informationConsolidation and maintenance therapy for transplant eligible myeloma patients
Consolidation and maintenance therapy for transplant eligible myeloma patients Teeraya Puavilai, M.D. Division of Hematology, Department of Medicine Faculty of Medicine Ramathibodi Hospital Mahidol University
More informationMultiple myeloma, 25 (45) years of progress. The IFM experience in patients treated with frontline ASCT. Philippe Moreau, Nantes
Multiple myeloma, 25 (45) years of progress The IFM experience in patients treated with frontline ASCT Philippe Moreau, Nantes Shibata T. Prolonged survival in a case of multiple myeloma treated with high
More informationHow I Treat Transplant Eligible Myeloma Patients
How I Treat Transplant Eligible Myeloma Patients Michele Cavo Seràgnoli Institute of Hematology, Bologna University School of Medicine, Italy Podcetrtek, Slovene, April 14 th, 2012 NEW TREATMENT PARADIGM
More informationTerapia del mieloma. La terapia di prima linea nel paziente giovane. Elena Zamagni
Terapia del mieloma La terapia di prima linea nel paziente giovane Elena Zamagni Istituto di Ematologia ed Oncologia Medica Seràgnoli Università degli Studi di Bologna Newly diagnosed MM Candidate for
More informationCOMy Congress The case for IMids. Xavier Leleu. Hôpital la Milétrie, PRC, CHU, Poitiers, France
Xavier Leleu Hôpital la Milétrie, PRC, CHU, Poitiers, France The case for IMids COMy Congress 21 Disclosures Grants/research support: Amgen, Bristol-Myers Squibb, Celgene, Janssen, Millennium/Takeda, Novartis,
More informationTiming of Transplant for Multiple Myeloma
Timing of Transplant for Multiple Myeloma Wenming CHEN Beijing Chaoyang Hospital Capital Medical University Multiple myeloma resrarch center of Beijing Initial Approach to Treatment of Myeloma Nontransplantation
More informationRole of Maintenance and Consolidation Therapy in Multiple Myeloma: A Patient-centered Approach
Role of Maintenance and Consolidation Therapy in Multiple Myeloma: A Patient-centered Approach Jacob Laubach, MD Assistant Professor in Medicine Harvard Medical School Clinical Director of the Jerome Lipper
More informationManaging Newly Diagnosed Multiple Myeloma
Managing Newly Diagnosed Multiple Myeloma 26 Jan 2018 Alfred Garfall, MD Assistant Professor of Medicine Diagnosis of Multiple Myeloma Traditional criteria: Monoclonal plasma cells + attributable CRAB
More informationMeu paciente realizou um TACTH na 1a linha, e agora? Tandem, Manutenção, Consolidação? Marcelo C Pasquini, MD, MS Medical College of Wisconsin
Meu paciente realizou um TACTH na 1a linha, e agora? Tandem, Manutenção, Consolidação? Marcelo C Pasquini, MD, MS Medical College of Wisconsin Post Auto HCT Options for MM Maintenance Lenalidomide vs.
More informationMultiple Myeloma Updates 2007
Multiple Myeloma Updates 2007 Brian Berryman, M.D. Multiple Myeloma Updates 2007 Goals for today: Understand the staging systems for myeloma Understand prognostic factors in myeloma Review updates from
More informationTo Maintain or Not to Maintain? Immunomodulators vs PIs Yes: Proteasome Inhibitors
To Maintain or Not to Maintain? Immunomodulators vs PIs Yes: Proteasome Inhibitors James Berenson, MD Institute for Myeloma and Bone Cancer Research West Hollywood, CA Financial Disclosures Takeda, Celgene
More informationRole of Stem Cell Transplantation in Multiple Myeloma: The Changing Landscape
Role of Stem Cell Transplantation in Multiple Myeloma: The Changing Landscape Simrit Parmar, MD MDACC Houston, TX, USA Why Transplant in the Era of Novel Therapy? Safe (TRM
More informationManagement of Multiple Myeloma: The Changing Paradigm
Management of Multiple Myeloma: The Changing Paradigm High-Dose Chemotherapy and Stem Cell Transplantation Todd Zimmerman, MD University of Chicago Medical Center Case Presentation R.M. is a 64 year old
More informationDisclosures for Palumbo Antonio, MD
Disclosures for Palumbo Antonio, MD Research Support/P.I. Employee Consultant Major Stockholder Speakers Bureau Honoraria Scientific Advisory Board o relevant conflicts of interest to declare o relevant
More informationHighlights from EHA Mieloma Multiplo
Highlights from EHA Mieloma Multiplo Michele Cavo Istituto di Ematologia L. e A. Seràgnoli Alma Mater Studiorum Università degli studi di Bologna Firenze, 22-23 Settembre 27 Myeloma XI TE pathway 7 R :
More informationNew Treatment Paradigms in Transplant-Eligible Myeloma Patients
New Treatment Paradigms in Transplant-Eligible Myeloma Patients Michele Cavo Seràgnoli Institute of Hematology, Bologna University School of Medicine, Italy Turkey, March 1 st 2013 NEW TREATMENT PARADıGM
More informationUnmet Medical Needs and Latest Multiple Myeloma Treatment
Unmet Medical Needs and Latest Multiple Myeloma Treatment Professor Chng Wee Joo Director National University Cancer Institute of Singapore (NCIS) National University Health System (NUHS) Deputy Director
More informationClinical Case Study Discussion: Maintenance in MM
www.comtecmed.com/comy comy@comtecmed.com Evangelos Terpos, MD, PhD National & Kapodistrian University of Athens, School of Medicine, Athens, Greece Clinical Case Study Discussion: Maintenance in MM Disclosure
More informationMULTIPLE MYELOMA. TREATMENT in 2017 MC. VEKEMANS
MULTIPLE MYELOMA TREATMENT in 2017 MC. VEKEMANS NATURAL HISTORY of MM WHO SHOULD BE TREATED? DEFINITION MGUS Smouldering Multiple Myeloma Symptomatic Multiple Myeloma Monoclonal component (blood and/or
More informationUpdate on Multiple Myeloma Treatment
Update on Multiple Myeloma Treatment Professor Chng Wee Joo Director National University Cancer Institute of Singapore (NCIS) National University Health System (NUHS) Deputy Director Cancer Science Institute,
More informationProgress in Multiple Myeloma
Progress in Multiple Myeloma Sundar Jagannath, MD Professor, New York Medical College Adjunct Professor, New York University St. Vincent s Comprehensive Cancer Center, NY Faculty Disclosure Advisory Board:
More informationCOMy Congress A New Era of Advances in Myeloma. S. Vincent Rajkumar Professor of Medicine Mayo Clinic
A New Era of Advances in Myeloma S. Vincent Rajkumar Professor of Medicine Mayo Clinic Scottsdale, Arizona Rochester, Minnesota Jacksonville, Florida Mayo Clinic College of Medicine Mayo Clinic Comprehensive
More informationMaintenance therapy after autologous transplantation
Maintenance therapy after autologous transplantation Sonja Zweegman MD PhD Department of Hematology Amsterdam The Netherlands Disclosures Research funding from Celgene, Takeda and Janssen Participation
More informationConsolidation after Autologous Stem Cell Transplantion
Consolidation after Autologous Stem Cell Transplantion Joan Bladé Laura Rosiñol Department of Hematology Hospital Clínic de Barcelona Berlin, September 11 th 2011 Autologous Stem Cell Transplant in Younger
More informationContinuous Therapy as a Standard of Care CON. JL Harousseau Institut de Cancérologie de l Ouest Nantes Saint Herblain France
Continuous Therapy as a Standard of Care CON JL Harousseau Institut de Cancérologie de l Ouest Nantes Saint Herblain France 1 In France and in the IFM all debates 2 In France and in the IFM all debates
More informationVI. Autologous stem cell transplantation and maintenance therapy
Hematological Oncology Hematol Oncol 2013; 31 (Suppl. 1): 42 46 Published online in Wiley Online Library (wileyonlinelibrary.com).2066 Supplement Article VI. Autologous stem cell transplantation and maintenance
More informationIn-depth look at specific data-sets; which ones meet requirements? Individual data owners /cooperative groups
In-depth look at specific data-sets; which ones meet requirements? Individual data owners /cooperative groups Minimal Residual Disease (MRD) by Multiparameter Flow Cytometry (MFC) in transplant eligible
More informationInduction Therapy: Have a Plan. Sagar Lonial, MD Professor, Winship Cancer Institute Director of Translational Research, B-cell Malignancy Program
Induction Therapy: Have a Plan Sagar Lonial, MD Professor, Winship Cancer Institute Director of Translational Research, B-cell Malignancy Program Topics When to treat? Smoldering vs Symptomatic Risk stratification
More informationNovel Combination Therapies for Untreated Multiple Myeloma
Novel Combination Therapies for Untreated Multiple Myeloma Andrzej J. Jakubowiak, MD, PhD Director, Myeloma Program New York, NY, October 27, 201 Disclosures 2 Employee Consultant Major Stockholder Speakers
More informationNovel Therapies for the Treatment of Newly Diagnosed Multiple Myeloma
Novel Therapies for the Treatment of Newly Diagnosed Shaji K. Kumar, MD Professor of Medicine Mayo Clinic College of Medicine Consultant, Division of Hematology Medical Director, Cancer Clinical Research
More informationStandard of care for patients with newly diagnosed multiple myeloma who are not eligible for a transplant
Standard of care for patients with newly diagnosed multiple myeloma who are not eligible for a transplant Pr Philippe Moreau University Hospital, Nantes, France MP: Standard of care until 2007 J Clin Oncol
More informationApproach to the Treatment of Newly Diagnosed Multiple Myeloma. S. Vincent Rajkumar Professor of Medicine Mayo Clinic
Approach to the Treatment of Newly Diagnosed Multiple Myeloma S. Vincent Rajkumar Professor of Medicine Mayo Clinic Scottsdale, Arizona Rochester, Minnesota Jacksonville, Florida Mayo Clinic College of
More informationChoosing upfront and salvage therapy for myeloma in the ASEAN context
Choosing upfront and salvage therapy for myeloma in the ASEAN context Daryl Tan Consultant Department of Haematology Singapore General Hospital Adjunct Assistant Professor Duke-NUS Graduate Medical School
More informationAutologous Stem Cell Transplanation as First line Treatment? (Against) Joan Bladé Berlin, September 9 th, 2011
Autologous Stem Cell Transplanation as First line Treatment? (Against) Joan Bladé Berlin, September 9 th, 2011 Significant impact of ASCT before the availability of novel agents? Randomized trials: Single
More informationCuring Myeloma So Close and Yet So Far! Luciano J. Costa, MD, PhD Associate Professor of Medicine University of Alabama at Birmingham
Curing Myeloma So Close and Yet So Far! Luciano J. Costa, MD, PhD Associate Professor of Medicine University of Alabama at Birmingham What is cure after all? Getting rid of it? Stopping treatment without
More informationCME Information LEARNING OBJECTIVES
CME Information LEARNING OBJECTIVES Identify patients with MM who have undergone autologous stem cell transplant and would benefit from maintenance lenalidomide. Counsel older patients (age 65 or older)
More informationStem Cell Transplant for Myeloma: The New Landscape
Stem Cell Transplant for Myeloma: The New Landscape Sergio A. Giralt, MD Chief, Adult Bone Marrow Transplant Service Division of Hematologic Oncology Department of Medicine Memorial Sloan-Kettering Cancer
More informationPost Transplant Maintenance- for everyone? Disclosures
Post Transplant Maintenance- for everyone? NO Because of limited survival data, not all patients require maintenance April 2012 Scottsdale, Arizona Rochester, Minnesota Jacksonville, Florida Joseph Mikhael,
More informationUK MRA Myeloma XII Relapsed Intensive Study CI: Prof Gordon Cook
UK Myeloma Research Alliance Myeloma XII study (ACCoRD): Augmented Conditioning & Consolidation in Relapsed Disease UK MRA Myeloma XII Relapsed Intensive Study CI: Prof Gordon Cook Sponsor ID: Pending
More informationChristine Chen Princess Margaret Cancer Centre September 2013
Christine Chen Princess Margaret Cancer Centre September 2013 Disclosures Research Support Celgene, Janssen, GSK Employee N/A Consultant N/A Major Stockholder Speakers Bureau/ Scientific Advisory Board
More informationWhat New in Hematopoietic Stem Cell Transplantation? Joseph M. Tuscano, M.D. UCD Cancer Center
What New in Hematopoietic Stem Cell Transplantation? Joseph M. Tuscano, M.D. UCD Cancer Center 1 JOSEPH TUSCNO, MD WHAT S NEW IN HEMATOPOEITIC STEM CELL TRANSPLANTATION? RELEVANT FINANCIAL RELATIONSHIPS
More information2015 Updates in Multiple Myeloma
2015 Updates in Multiple Myeloma Siddhartha Ganguly, MD, FACP Professor of Medicine Director, Lymphoma and Myeloma Blood and Marrow Transplantation Program The University of Kansas Medical Center 1 Earliest
More informationTransplant in MM patients: Early versus late. Mario Boccadoro. Barcelona
Transplant in MM patients: Early versus late Barcelona 8-9-2012 Mario Boccadoro DIVISIONE UNIVERSITARIA DI EMATOLOGIA AZIENDA OSPEDALIERA SAN GIOVANNI TORINO, ITALY Transplant in MM patients: Early versus
More informationCREDIT DESIGNATION STATEMENT
CME Information LEARNING OBJECTIVES Integrate emerging research information on the use of proteasome inhibitors and immunomodulatory agents to individualize induction treatment recommendations and maintenance
More informationAutologous Stem Cell Transplantation in Multiple Myeloma Optimal Frontline Therapy and Maintenance Therapy
Autologous Stem Cell Transplantation in Multiple Myeloma Optimal Frontline Therapy and Maintenance Therapy Donna E. Reece, M.D. Princess Margaret Hospital Toronto, ON CANADA 10 December 2011 ASCT in Myeloma..
More informationHighlights in multiple myeloma
3 CONGRESS HIGHLIGHTS Highlights in multiple myeloma P. Vlummens, MD SUMMARY Multiple myeloma (MM) remains a devastating disease, even in the era of novel agents. As such, the search for new treatment
More informationCurrent Management of Multiple Myeloma. December 2012 Kevin Song MD FRCPC Leukemia/BMT Program of B.C.
Current Management of Multiple Myeloma December 2012 Kevin Song MD FRCPC Leukemia/BMT Program of B.C. Disclosures Honoraria Speaker Celgene, Janssen, Novartis Celgene, Janssen Research Support Celgene
More informationTreatment Advances in Multiple Myeloma: Expert Perspectives on Translating Clinical Data to Practice
Treatment Advances in Multiple Myeloma: Expert Perspectives on Translating Clinical Data to Practice Friday, December 2, 2016 San Diego, California This program is supported by educational grants from
More informationMultiple Myeloma: Diagnosis and Primary Treatment
Multiple Myeloma: Diagnosis and Primary Treatment George Somlo, MD City of Hope Comprehensive Cancer Center NCCN.org For Clinicians NCCN.org/patients For Patients Educational Objectives Discuss considerations
More informationIl trattamento del Mieloma su stratificazione di rischio: è oggi possibile?
Il trattamento del Mieloma su stratificazione di rischio: è oggi possibile? Francesca Gay, MD Divisione Ematologia 1 AO Città della Salute e della Scienza, Torino, Italy Focus sul MM 2014 Cagliari, 30-31
More informationLONDON CANCER NEWS DRUGS GROUP RAPID REVIEW
LONDON CANCER NEWS DRUGS GROUP RAPID REVIEW Bortezomib as first line induction prior to melphalan and autologous stem cell transplantation (ASCT) in untreated symptomatic multiple myeloma patients suitable
More informationGetting Clear Answers to Complex Treatment Challenges in Multiple Myeloma: Case Discussions
Getting Clear Answers to Complex Treatment Challenges in Multiple Myeloma: Case Discussions Friday, December 8, 2017 Atlanta, Georgia Friday Satellite Symposium preceding the 59th ASH Annual Meeting &
More informationMYELOMA MAINTENANCE BEST PRACTICES:
MYELOMA MAINTENANCE BEST PRACTICES: POST THERAPY & POST TRANSPLANT Aric Hall, MD Assistant Professor University of Wisconsin Hospital and Clinics INTRODUCTION MYELOMA Clonal plasma cell malignancy leading
More informationMultiple Myeloma: ASH 2008
Multiple Myeloma: ASH 2008 Steven Coutre, M.D. Associate Professor of Medicine Division of Hematology Stanford University School of Medicine About These Slides These slides accompany CCO s comprehensive
More informationStudy Objectives: GMMG MM5
Study Objectives: GMMG MM5 1.) Demonstration of non-inferiority of VCD induction therapy compared to PAd induction therapy with respect to response rate (very good partial remission or better; response
More informationManagement of high-risk disease
Management of high-risk disease Pieter Sonneveld Erasmus MC Cancer Institute Rotterdam The Netherlands Disclosures Research support : Amgen, Celgene, Janssen, Karyopharm Advisory Boards/Honoraria: BMS,
More informationNew IMWG Response Criteria
New IMWG Response Criteria Shaji Kumar, M.D. Professor of Medicine Division of Hematology Mayo Clinic Scottsdale, Arizona Rochester, Minnesota Jacksonville, Florida Mayo Clinic College of Medicine Mayo
More informationTo Maintain or Not to Maintain? Lymphoma and Myeloma 2015 Waldorf Astoria Hotel, New York
To Maintain or Not to Maintain? Lymphoma and Myeloma 2015 Waldorf Astoria Hotel, New York Sundar Jagannath Director, Multiple Myeloma Program Tisch Cancer Institute Mount Sinai Medical Center Maintenance
More informationRisk stratification in the older patient; what are our priorities?
Risk stratification in the older patient; what are our priorities? Sonja Zweegman MD PhD Amsterdam The Netherlands Negative impact of age on survival Meta-analysis of European trials (MP vs MPT, VMP vs
More informationManagement of Multiple
Management of Multiple Myeloma in the Elderly Xavier Leleu Service des Maladies du Sang Hôpital Huriez, CHRU, Lille, France INSERM U837, équipe 3 IRCL, CHRU, Lille, France IMPRT Institut de Médecine Prédictive
More informationMAINTENANCE AND CONTINUOUS THERAPY OF MYELOMA. Myeloma Day 11/18/2017 Aric Hall, MD Assistant Professor UW School of Medicine & Public Health
MAINTENANCE AND CONTINUOUS THERAPY OF MYELOMA Myeloma Day 11/18/2017 Aric Hall, MD Assistant Professor UW School of Medicine & Public Health Disclosures I have no significant conflicts of interest to disclose.
More informationMyeloma and renal failure Future directions. Karthik Ramasamy
Myeloma and renal failure Future directions Karthik Ramasamy Overview Historical perspective & Background Drug interventions & trials OPTIMAL Trial Future directions Burden of disease Upto 40% of newly
More informationTreatment of elderly multiple myeloma patients
SAMO Interdisciplinary Workshop on Myeloma March 30 th -31 st 2012, Seehotel Hermitage, Lucerne Treatment of elderly multiple myeloma patients Federica Cavallo, MD, PhD Federica Cavallo, MD, PhD Division
More informationDebate: Is transplant a necessity or a choice? Focus on the necessity for CR and MRD. Answer: NO
Debate: Is transplant a necessity or a choice? Focus on the necessity for CR and MRD. Answer: NO Tomer M. Mark Department of Medicine, Division of Hematology / Oncology Weill-Cornell Medical College /
More informationMultiple Myeloma: Induction, Consolidation and Maintenance Therapy
Multiple Myeloma: Induction, Consolidation and Maintenance Therapy James R. Berenson, MD Medical & Scientific Director Institute for Myeloma & Bone Cancer Research Los Angeles, CA Establish the Goals of
More informationAdvances in the Management of Myeloma Parameswaran Hari, MD
Advances in the Management of Myeloma Parameswaran Hari, MD Medical College of Wisconsin Milwaukee, WI What is the standard? Induction/Transplant/Maintenance UPDATED OS DATA from CALGB 100104 & IFM 2005-02
More informationTREATMENT FOR NON-TRANSPLANT ELIGIBLE MULTIPLE MYELOMA
TREATMENT FOR NON-TRANSPLANT ELIGIBLE MULTIPLE MYELOMA Ekarat Rattarittamrong, MD Division of Hematology Department of Internal Medicine Faculty of Medicine Chiang Mai University OUTLINE Overview of treatment
More informationUpfront Therapy for Myeloma Tailoring Therapy across the Disease Spectrum
Upfront Therapy for Myeloma Tailoring Therapy across the Disease Spectrum S. Vincent Rajkumar Professor of Medicine Mayo Clinic Scottsdale, Arizona Rochester, Minnesota Jacksonville, Florida Mayo Clinic
More informationHow to treat a newly diagnosed young patient with multiple myeloma
How to treat a newly diagnosed young patient with multiple myeloma J.F. San Miguel University of Salamanca, Spain Department of Haematology University of Salamanca Cancer Research Centre Disclosures for
More informationInduction Therapy & Stem Cell Transplantation for Myeloma
Induction Therapy & Stem Cell Transplantation for Myeloma William Bensinger, MD Professor of Medicine, Division of Oncology University of Washington School of Medicine Director, Autologous Stem Cell Transplant
More informationIMiDs (Immunomodulatory drugs) and Multiple Myeloma
www.comtecmed.com/comy comy@comtecmed.com IMiDs (Immunomodulatory drugs) and Multiple Myeloma Xavier Leleu Service des Maladies du Sang Hôpital Huriez, CHRU, Lille, France www.comtecmed.com/comy comy@comtecmed.com
More informationMichel Delforge Belgium. New treatment options for multiple myeloma
Michel Delforge Belgium New treatment options for multiple myeloma Progress in the treatment of MM over the past 40 years 1962 Prednisone + melphalan 1990s Supportive care 1999 First report on thalidomide
More informationMyeloma update ASH 2014
Myeloma update ASH 2014 Updates in Newly Diagnosed Multiple Myeloma FIRST: effect of age on lenalidomide/dexamethasone vs MPT in transplantation-ineligible pts Phase III: MPT-T vs MPR-R in transplantation-ineligible
More informationMultiple Myeloma Brian Berryman, M.D. March 8 th, 2014
Multiple Myeloma 2014 Brian Berryman, M.D. March 8 th, 2014 Kyle, R. A. et al. Blood 2008;111:2962-2972 Updates in Multiple Myeloma CCO Independent Conference Coverage of the 2013 Annual Meeting of
More informationTreatment of elderly patients with multiple myeloma
Treatment of elderly patients with multiple myeloma Mario Boccadoro DIVISIONE UNIVERSITARIA DI EMATOLOGIA AZIENDA OSPEDALIERA SAN GIOVANNI TORINO, ITALY Improved survival in multiple myeloma and the impact
More informationDr Shankara Paneesha. ASH Highlights Department of Haematology & Stem cell Transplantation
ASH Highlights 2015 Themes of ASH 2015 Novel therapies - Myeloma AML Lymphoma Pd-L1 & PD-l inhibitors Emerging concepts in biology HIF-1a pathway Cautionary tales ASH Choosing Wisely list IFM/DFCI
More informationASCO Analyst & Investor Webcast. June 1, 2018
ASCO Analyst & Investor Webcast June 1, 2018 June 1, 2018 NASDAQ: BLUE Forward Looking Statements These slides and the accompanying oral presentation contain forward-looking statements and information
More informationAntibodies are a standard part of first relapse management in multiple myeloma (MM): Yes
Antibodies are a standard part of first relapse management in multiple myeloma (MM): Yes Ajay Nooka, MD MPH FACP Assistant Professor, Division of Bone Marrow Transplant Winship Cancer Institute, Emory
More informationIs Transplant a Necessity or a Choice: Focus on the necessity for CR and MRD
Is Transplant a Necessity or a Choice: Focus on the necessity for CR and MRD Ajai Chari, MD Associate Professor of Medicine Director of Clinical Research Multiple Myeloma Program Mount Sinai Medical Center
More informationHow to Integrate the New Drugs into the Management of Multiple Myeloma
How to Integrate the New Drugs into the Management of Multiple Myeloma Carol Ann Huff, MD The Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins NCCN.org For Clinicians NCCN.org/patients For Patients
More informationExperience with bortezomib (Velcade) in multiple myeloma. Peter Černelč Clinical center Ljubljana Department of Haematology
Experience with bortezomib (Velcade) in multiple myeloma Peter Černelč Clinical center Ljubljana Department of Haematology Our experience with bortezomib (Velcade) in multiple myeloma 1. Our first experience
More informationGetting Clear Answers to Complex Treatment Challenges in Multiple Myeloma: Case Discussions
Getting Clear Answers to Complex Treatment Challenges in Multiple Myeloma: Case Discussions Friday, December 8, 2017 Atlanta, Georgia Friday Satellite Symposium preceding the 59th ASH Annual Meeting &
More informationMaking Sense of Myeloma Treatment Advances
Making Sense of Myeloma Treatment Advances Webinar 1, May 17, 217 Updates From the 16th International Myeloma Workshop and the American Association for Cancer Research 217 Annual Meeting Speakers Moderator:
More informationTreatment Strategies for Transplant-ineligible NDMM Patients
1 Treatment Strategies for Transplant-ineligible NDMM Patients Thierry Facon, MD Professor of Hematology Service des Maladies du Sang University of Lille Lille, France Multiple Myeloma affects primarily
More informationAutologous Hematopoietic Stem Cell Transplantation and Mobilization in Multiple Myeloma:
Autologous Hematopoietic Stem Cell Transplantation and Mobilization in Multiple Myeloma: Current Debate and Developments This transcript has been edited for style and clarity and includes all slides from
More informationMultiple Myeloma in 2016 Progress and Challenges DONNA E. REECE, M.D. PRINCESS MARGARET CANCER CENTRE 01 APRIL 2016
Multiple Myeloma in 2016 Progress and Challenges DONNA E. REECE, M.D. PRINCESS MARGARET CANCER CENTRE 01 APRIL 2016 Key Features of Myeloma Biology Myeloma is not one disease 1 At least 7 subtypes based
More informationRelapsed Myeloma Sequencing Treatments
Relapsed Myeloma Sequencing Treatments Noopur Raje, MD Director, Center for Multiple Myeloma MGH Cancer Center Professor of Medicine Harvard Medical School Disclosures Consultant /Advisory Board: Celgene,
More informationTopics. When to treat? Smoldering vs Symptomatic Choice of Induction regimen Role of HDT Role of consolidation/maintenance
Initial Therapy Sagar Lonial, MD Chair and Professor Department of Hematology and Medical Oncology Chief Medical Officer, Winship Cancer Institute Emory University School of Medicine Topics When to treat?
More informationManagement of Multiple Myeloma
Management of Multiple Myeloma Damian J. Green, MD Fred Hutchinson Cancer Research Center/ Seattle Cancer Care Alliance New Treatment Options Have Improved OS in MM Kumar SK, et al. Blood. 2008;111:2516-2520.
More informationKalyan Nadiminti, MBBS 4/13/18
A Single Autologous Stem Cell Transplant (ASCT) followed by two years of post-transplant therapy is safe in Older Recently Diagnosed Multiple Myeloma (MM) Patients. Preliminary Results from the Prospective
More informationUpdates in Multiple Myeloma: 12 months in 10 minutes
Updates in Multiple Myeloma: 12 months in 10 minutes Aaron Rosenberg MD, MS Assistant Prof. Medicine UC Davis Comprehensive Cancer Center Division of Hematology and Oncology Outline Standard of care for
More informationMULTIPLE MYELOMA. The clonoseq Assay can predict progressionfree survival in myeloma patients
MULTIPLE MYELOMA With current therapies, complete response (CR) is reached in 3-5% of multiple myeloma () patients. 1 However, most of these patients will experience relapse due to the persistence of residual
More informationNew Strategies for Multiple Myeloma Care: Next Steps for the Future
Jointly provided by the Annenberg Center for Health Sciences at Eisenhower, International Myeloma Foundation, and Clinical Care Options, LLC New Strategies for Multiple Myeloma Care: Next Steps for the
More informationBest of ASH 2017 DR. BRIAN DURIE. Brian GM Durie, MD Thursday, January 11, 2018
Best of ASH 2017 DR. BRIAN DURIE Brian GM Durie, MD Thursday, January 11, 2018 1 ASH Overview 2017 Total myeloma abstracts: 981 Important/Interesting: oral ~40 posters ~60 100 2 Which abstracts impact
More informationMultiple Myeloma Transplant and Non-transplant Modalities
Multiple Myeloma Transplant and Non-transplant Modalities Sikander Ailawadhi, MD Associate Professor of Medicine Division of Hematology-Oncology Mayo Clinic, Jacksonville, Florida 15 th Annual Miami Cancer
More informationPosttransplantation Maintenance Therapy and Optimal Frontline Therapy in Myeloma
CONTROVERSIES AND UPDATES IN MULTIPLE MYELOMA Posttransplantation Maintenance Therapy and Optimal Frontline Therapy in Myeloma Donna E. Reece 1 1 Princess Margaret Hospital, Toronto, ON One of the major
More information